Table 1.
Demographic and ocular characteristics of patients before treatment and 12, 24 and 36 weeks after intravitreal diclofenac injection
| BCVA (LogMAR) | CMT (microns) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number | Sex | Eye | Age | Diagnosis | Baseline | Week 12 | Week 24 | Week 36 | Change from baseline to week 36 | Baseline | Week 12 | Week 24 | Week 36 | Change from baseline to week 36 |
| 1 | M | OD | 56 | Intermediate non-granulomatousuveitis | 0.60 | 0.18 | 0.18 | 0.18 | -0.42 | 484 | 270 | 254 | 245 | -239 |
| 2 | F | OS | 58 | " | 0.54 | 0.54 | 0.54 | 0.70 | +0.16 | 437 | 423 | 412 | 407 | -30 |
| 3 | F | OD | 57 | " | 0.90 | 1.10 | 1.2 | 1.0 | +0.1 | 345 | 294 | 187 | 223 | -122 |
| 4 | F | OD | 41 | " | 0.78 | 0.78 | 1.0 | 0.60 | -0.18 | 584 | 756 | 780 | 646 | +62 |
| 5 | F | OS | 36 | " | 0.40 | 0.50 | 0.40 | 0.30 | -0.1 | 518 | 522 | 373 | 288 | -230 |
| 6 | F | OS | 35 | " | 0.40 | 0.30 | 0.40 | 0.40 | 0 | 476 | 465 | 437 | 416 | -60 |
| 7 | F | OD | 47 | " ‘ | 1.30 | 0.78 | 0.78 | 0.90 | -0.4 | 390 | 294 | 452 | 705 | +315 |
| 8 | F | OS | 43 | Intermediate granulomatous uveitis | 0.78 | 1.30 | 1.10 | 1.00 | +0.22 | 672 | 490 | 437 | 721 | +49 |
| Mean | - | - | 47 | - | 0.71 | 0.69 | 0.70 | 0.64 | -0.08 | 488 | 439 | 416 | 456 | -32 |
| (SD) | (0.30) | (0.38) | (0.37) | (0.32) | (0.24) | (105) | (161) | (175) | (207) | (180) | ||||
| P-value forchange from baseline (Wilcoxon Signed rank test) | 0.916 | 0.686 | 0.446 | 0.123 | 0.208 | 0.575 | ||||||||
BCVA, best-corrected visual acuity; CMT, central macular thickness; M, male; F, female; OD, right eye; OS, left eye; SD, standard deviation